A new perspective in the research of antibody drug conjugate

Antibody drug conjugate (ADC) combines the high specificity of monoclonal antibodies and the high activity of small molecule cytotoxic drugs through linkers to improve the targeting of tumor drugs and reduce the toxic side effects. Due to the advantages of clear targets, mature technology, and good selectivity, ADCs have shown excellent application prospects in hematological and solid tumor therapeutic fields. In this perspective, the selection of ADC-targeting antigens is described in the group of driver gene target antigens and non-driver gene target antigens to make more evident the importance of targeting antigens in advancing ADCs for tumor therapy. In the future, continued research and innovation in this field will help provide more effective, targeted, and personalized treatments for cancer patients, ultimately improving patients’ outcomes and quality of life.